Omeros (NASDAQ:OMER) Now Covered by Analysts at Cantor Fitzgerald

Equities researchers at Cantor Fitzgerald started coverage on shares of Omeros (NASDAQ:OMER) in a note issued to investors on Monday, May 6th, MarketBeat.com reports. The brokerage set an “overweight” rating and a $26.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 46.23% from the stock’s previous close.

Several other research analysts also recently commented on the stock. ValuEngine raised shares of Omeros from a “hold” rating to a “buy” rating in a report on Tuesday, January 15th. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price objective on shares of Omeros in a report on Monday, March 4th. Finally, Zacks Investment Research downgraded shares of Omeros from a “hold” rating to a “sell” rating in a report on Thursday, February 21st. One investment analyst has rated the stock with a sell rating, two have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $26.50.

Shares of Omeros stock traded down $0.65 on Monday, reaching $17.78. 331,308 shares of the company traded hands, compared to its average volume of 572,863. Omeros has a 52 week low of $10.30 and a 52 week high of $27.00. The company has a market capitalization of $879.16 million, a P/E ratio of -8.01 and a beta of 3.57.

Omeros (NASDAQ:OMER) last released its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.34) by ($0.04). The firm had revenue of $21.80 million for the quarter, compared to analysts’ expectations of $23.18 million. The firm’s revenue for the quarter was up 1271.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.62) earnings per share. As a group, research analysts expect that Omeros will post -1.44 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of OMER. Advisory Services Network LLC purchased a new stake in Omeros in the 1st quarter worth approximately $69,000. Legal & General Group Plc lifted its stake in Omeros by 12.7% in the 4th quarter. Legal & General Group Plc now owns 8,370 shares of the biopharmaceutical company’s stock worth $93,000 after purchasing an additional 945 shares in the last quarter. Great West Life Assurance Co. Can lifted its stake in Omeros by 129.5% in the 1st quarter. Great West Life Assurance Co. Can now owns 7,683 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 4,336 shares in the last quarter. Rocky Mountain Advisers LLC raised its position in shares of Omeros by 8.5% during the 4th quarter. Rocky Mountain Advisers LLC now owns 12,760 shares of the biopharmaceutical company’s stock valued at $142,000 after buying an additional 1,000 shares in the last quarter. Finally, Keeley Teton Advisors LLC raised its position in shares of Omeros by 8.9% during the 4th quarter. Keeley Teton Advisors LLC now owns 13,001 shares of the biopharmaceutical company’s stock valued at $145,000 after buying an additional 1,060 shares in the last quarter. Institutional investors and hedge funds own 52.12% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Featured Story: Special Dividends

Analyst Recommendations for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.